November 2018 Vol. 6 No.11

Abstract
• Full text
•Reprint (PDF) (865 KB)

Search Pubmed for articles by:
 

Original Research Article

Expression of E-Cadherin, Her2/neu, and P53 in endometrial carcinoma: Relation to different clinicopathological predictors of the prognosis

Nahed Soliman^1*, Sahar Ali Mohamed² and Deaa Fekri Morsi³

¹Department of Pathology, Faculty of Medicine, Helwan University, Egypt / Department of Pathology, Faculty of Medicine, Mansoura University, Egypt (2000-2016)
²Pathology Lab, El Galaa Teaching Hospital, Egypt
³Department of Pathology, Faculty of Medicine, Helwan University, Egypt. And Department of Pathology, Faculty of Medicine, Alazhar University, Egypt. Email address: deaafekri@gmail.com

*Corresponding Authors Emails: nahed.soliman@med.helwan.edu.eg
nahedram@yahoo.com
deaa.fekri@med.helwan.edu.eg

Accepted November 12, 2018

Abstract

Background: Endometrial carcinoma is one of the commonest cancers in woman. E Cadherin, Her2/neu, and P53 had an important role in predicting the prognosis of endometrial carcinoma. The objective is to evaluate expression of E-cadherin, HER2/neu and p53 in Endometrial Carcinoma and to find their relationship with clinicopathological characteristics. Material and Methods: 92 specimens were tested for E- cadherin, HER-2/neu and p53 expression using immunohistochemical analysis. The significance of association of expression of the markers with clinicopathological parameters was assessed. Results: Significant association of E- cadherin overexpression with endometrioid type (P=0.001). While this was not the case as regard HER2 or p53. P53 was significantly related to high grade (P=0.02). There was statistically significant association between myometrial invasion and either E- cadherin expression or P53 (P=0.01, 0.03) respectively. There was significant considerable negative correlation between E- cadherin and p53 expression (P=0.000, co: -0.428). Conclusion: E- cadherin expression is good predictor of the prognosis of endometrial cancer than proliferation marker HER2/neu or p53. Endometrial cancer–specific HER2 IHC testing and scoring guidelines need to be developed in the future to reflect the unique biology and pathogenetic features of these tumors.

Keyword: Endometrial carcinoma, endometrioid, E Cadherin, Her2/neu, and P53